// App-Quantinova.ai

1409 : Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

Researchers

Presenter

  • Kenshi Suzuki

Principal Investigators

  • Kihyun Kim

  • Chihiro Shimazaki

  • Jin Seok Kim

  • Takayuki Ikezoe

  • Chang-Ki Min

  • Fude Zhou

  • Shinsuke Iida

  • Nagaaki Katoh

  • Tomoaki Fujisaki

  • Ho-Jin Shin

  • NamPhuong Tran

  • Xiang Qin

  • Sandra Y. Vasey

  • Brenda Tromp

  • Brendan M. Weiss

  • Jessica Vermeulen

  • Raymond L. Comenzo

  • Efstathios Kastritis

  • Jin Lu

Medical Centers

  • Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan

  • University College London and the Royal Free London NHS Foundation Trust, Division of Medicine, Faculty of Medical Sciences, London, United Kingdom

  • Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)

  • JCHO Kyoto Kuramaguchi Medical Center, Department of Hematology, Kyoto, Japan

  • 3Neurology, Korea University Guro Hospital Seoul Korea, Republic of

  • Department of Hematology, Fukushima Medical School, Fukushima, Japan

  • St Vincents Hospital, Seoul, Korea, Republic of (South)

  • Peking University First Hospital Renal Division- Department of Medicine Beijing China

  • Department of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan

  • Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan

  • Matsuyama Red Cross Hospital, Matsuyama, Japan

  • Division of Nephrology, Department of Internal Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of

  • Janssen Research & Development, Los Angeles, CA

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Biologics, Leiden, Netherlands

  • Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece

  • Peking University People’s Hospital, National Clinical Research Center for Hematologic Disease, Collaborative Innovation Center of Hematology, Beijing, China

Locations

  • Japan

  • United Kingdom

  • Republic of South Korea

  • China

  • United States

  • Netherlands

  • Greece

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • AL Amyloidosis

  • Renal insufficiency

  • Amyloid disease

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Hyaluronidase

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • daratumumab Intravenous

  • Bortezomib

  • Enhanze

  • rHuPH20

  • Sparsentan

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved